Physician profile
John T Ducker
NPI 1003868597
$8,250.60
in general payments reported to CMS, 2019-2025
27 companies · $3,785 in 2025
The $3,785 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $420 · 2021: $879 · 2022: $783 · 2023: $1,109 · 2024: $671 · 2025: $3,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,021 · Food and Beverage: $2,438 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,020.63 |
| Food and Beverage | $2,437.50 |
| Education | $107.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $3,698.12 | 2019-2025 | Optiflux, Nxstage System One, Korsuva |
| Astrazeneca Pharmaceuticals Lp | $1,079.74 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $536.60 | 2019-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $514.56 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $315.94 | 2020-2025 | Jynarque |
| Akebia Therapeutics INC | $270.74 | 2019-2022 | |
| Nxstage Medical, INC. | $252.78 | 2019-2024 | Nxstage System One, Liberty Select Cycler |
| Amgen INC. | $198.95 | 2019-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $179.82 | 2023-2025 | Filspari |
| Eurofins Viracor, LLC | $179.58 | 2019 | |
| Opko Pharmaceuticals, LLC | $166.09 | 2019-2024 | Rayaldee |
| Horizon Therapeutics Plc | $135.18 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $117.38 | 2021-2024 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $82.95 | 2021-2024 | Lupkynis |
| Outset Medical INC | $71.63 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $58.42 | 2023-2025 | |
| Daiichi Sankyo INC. | $54.56 | 2019-2023 | Injectafer |
| Baxter Healthcare | $54.53 | 2019 | |
| Calliditas Therapeutics US INC. | $49.40 | 2023 | Tarpeyo |
| Lilly USA, LLC | $43.08 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $40.08 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $35.87 | 2019 | |
| Glaxosmithkline, LLC. | $28.71 | 2022-2024 | Benlysta, Jesduvroq |
| Novo Nordisk INC | $27.44 | 2025 | Ozempic |
| Scpharmaceuticals INC. | $24.31 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $19.99 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $14.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ducker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.